{"id":"sibutramine","rwe":[],"tags":[{"label":"Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium-dependent serotonin transporter","category":"target"},{"label":"SLC6A4","category":"gene"},{"label":"SLC6A3","category":"gene"},{"label":"ADRA2B","category":"gene"},{"label":"A08AA10","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Obesity","category":"indication"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Obesity Agents","category":"pharmacology"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Appetite Depressants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":61.241,"date":"","count":22,"signal":"Tachycardia","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=61)"},{"llr":57.619,"date":"","count":8,"signal":"Suspected counterfeit product","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=58)"}],"drugInteractions":[{"url":"/drug/citalopram","drug":"citalopram","action":"Avoid combination","effect":"May interact with Citalopram, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"citalopram"},{"url":"/drug/desvenlafaxine","drug":"desvenlafaxine","action":"Monitor closely","effect":"May interact with Desvenlafaxine, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"desvenlafaxine"},{"url":"/drug/escitalopram","drug":"escitalopram","action":"Avoid combination","effect":"May interact with Escitalopram Oxalate, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"escitalopram"},{"url":"/drug/fluoxetine","drug":"fluoxetine","action":"Avoid combination","effect":"May interact with Fluoxetine, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"fluoxetine"},{"url":"/drug/fluvoxamine","drug":"fluvoxamine","action":"Avoid combination","effect":"May interact with Fluvoxamine Maleate, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"fluvoxamine"},{"url":"/drug/naratriptan","drug":"naratriptan","action":"Avoid combination","effect":"May interact with Naratriptan Hydrochloride, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"naratriptan"},{"url":"/drug/nefazodone","drug":"nefazodone","action":"Avoid combination","effect":"May interact with Nefazodone, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"nefazodone"},{"url":"/drug/paroxetine","drug":"paroxetine","action":"Avoid combination","effect":"May interact with Paroxetine, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"paroxetine"},{"url":"/drug/sertraline","drug":"sertraline","action":"Avoid combination","effect":"May interact with Sertraline, Sibutramine Hydrochloride","source":"DrugCentral","drugSlug":"sertraline"},{"url":"/drug/sumatriptan","drug":"sumatriptan","action":"Avoid combination","effect":"May interact with Sibutramine Hydrochloride, Sumatriptan","source":"DrugCentral","drugSlug":"sumatriptan"},{"url":"/drug/tapentadol","drug":"tapentadol","action":"Monitor closely","effect":"May interact with Sibutramine Hydrochloride, Tapentadol","source":"DrugCentral","drugSlug":"tapentadol"},{"url":"/drug/tramadol","drug":"tramadol","action":"Monitor closely","effect":"May interact with Sibutramine Hydrochloride, Tramadol Hydrochloride","source":"DrugCentral","drugSlug":"tramadol"},{"url":"/drug/tranylcypromine","drug":"tranylcypromine","action":"Avoid combination","effect":"May interact with Sibutramine Hydrochloride, Tranylcypromine","source":"DrugCentral","drugSlug":"tranylcypromine"},{"url":"/drug/tryptophan","drug":"tryptophan","action":"Monitor closely","effect":"May interact with Sibutramine Hydrochloride, Tryptophan","source":"DrugCentral","drugSlug":"tryptophan"},{"url":"/drug/venlafaxine","drug":"venlafaxine","action":"Avoid combination","effect":"May interact with Sibutramine Hydrochloride, Venlafaxine Hydrochloride","source":"DrugCentral","drugSlug":"venlafaxine"},{"url":"/drug/zolmitriptan","drug":"zolmitriptan","action":"Avoid combination","effect":"May interact with Sibutramine Hydrochloride, Zolmitriptan","source":"DrugCentral","drugSlug":"zolmitriptan"}],"commonSideEffects":[],"contraindications":["Acute nephropathy","Angina pectoris","Angle-closure glaucoma","Anorexia nervosa","Blood coagulation disorder","Breastfeeding (mother)","Bulimia nervosa","Cardiovascular event risk","Cerebrovascular accident","Chronic heart failure","Chronic renal failure syndrome","Conduction disorder of the heart","Diabetes mellitus","Disorder of cardiovascular system","Disorder of coronary artery","Hepatic failure","Hypertensive disorder","Kidney disease","Myocardial infarction","Neuroleptic malignant syndrome","Peripheral arterial occlusive disease","Seizure disorder","Serotonin syndrome","Tachyarrhythmia","Transient ischemic attack"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SIBUTRAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:36:23.216505+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:36:30.339537+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SIBUTRAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:36:31.174784+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Monoamine transporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:36:31.752995+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989830/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:36:31.647470+00:00"}},"allNames":"racemic sibutramine","offLabel":[],"synonyms":["sibutramine","(+/-)-Sibutramine","didemethyl sibutramine hydrochloride","racemic sibutramine","sibutramine hydrochloride","sibutramine hydrochloride hydrate","BTS 54524","didemethyl sibutramine HCl","sibutramine HCl","didesmethylsibutramine"],"timeline":[{"date":"1997-11-22","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Racemic Sibutramine, also known as SIBUTRAMINE, is a small molecule Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic. It was originally developed and is currently owned by a pharmaceutical company. Sibutramine targets the sodium-dependent serotonin transporter, which is involved in regulating mood and appetite. It was FDA approved in 1997 for the treatment of obesity, but is now off-patent and no longer commercially available. As a result, there are no generic manufacturers of the drug.","approvals":[{"date":"1997-11-22","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Racemic Sibutramine","ecosystem":[{"indication":"Obesity","otherDrugs":[{"name":"amfetamine","slug":"amfetamine","company":"Ucb Inc"},{"name":"benzphetamine","slug":"benzphetamine","company":"Pharmacia And Upjohn"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"chlorphentermine","slug":"chlorphentermine","company":"Parke Davis"}],"globalPrevalence":890000000}],"mechanism":{"target":"Sodium-dependent serotonin transporter","novelty":"Follow-on","targets":[{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"CYP2B6","source":"DrugCentral","target":"Cytochrome P450 2B6","protein":"Cytochrome P450 2B6"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"KCND3","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily D member 3","protein":"Potassium voltage-gated channel subfamily D member 3"},{"gene":"SLC22A2","source":"DrugCentral","target":"Solute carrier family 22 member 2","protein":"Solute carrier family 22 member 2"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"}],"moaClass":"Dopamine Uptake Inhibitors","modality":"Small Molecule","drugClass":"Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic","explanation":"","oneSentence":"","technicalDetail":"Sibutramine acts as a reuptake inhibitor of serotonin, norepinephrine, and dopamine by binding to their respective transporters, thereby increasing their concentrations in the synaptic cleft and enhancing their effects on appetite regulation and mood."},"commercial":{"launchDate":"1997","_launchSource":"DrugCentral (FDA 1997-11-22, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2440","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SIBUTRAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SIBUTRAMINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:39:24.285292","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:36:33.531633+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"phentermine","drugSlug":"phentermine","fdaApproval":"1959-05-04","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenfluramine","drugSlug":"fenfluramine","fdaApproval":"2020-06-25","patentExpiry":"Nov 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diethylpropion","drugSlug":"diethylpropion","fdaApproval":"1959-08-06","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mazindol","drugSlug":"mazindol","fdaApproval":"1973-06-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lorcaserin","drugSlug":"lorcaserin","fdaApproval":"2012-06-27","relationship":"same-class"},{"drugName":"setmelanotide","drugSlug":"setmelanotide","fdaApproval":"2020-11-25","patentExpiry":"Oct 13, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"topiramate","drugSlug":"topiramate","fdaApproval":"1996-12-24","patentExpiry":"Nov 16, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"naltrexone","drugSlug":"naltrexone","fdaApproval":"1984-11-20","patentExpiry":"Oct 15, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"sibutramine","indications":{"approved":[{"name":"Obesity","source":"DrugCentral","snomedId":414916001,"regulator":"FDA","usPrevalence":100000000,"globalPrevalence":890000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"phentermine","brandName":"phentermine","genericName":"phentermine","approvalYear":"1959","relationship":"same-class"},{"drugId":"fenfluramine","brandName":"fenfluramine","genericName":"fenfluramine","approvalYear":"2020","relationship":"same-class"},{"drugId":"diethylpropion","brandName":"diethylpropion","genericName":"diethylpropion","approvalYear":"1959","relationship":"same-class"},{"drugId":"mazindol","brandName":"mazindol","genericName":"mazindol","approvalYear":"1973","relationship":"same-class"},{"drugId":"lorcaserin","brandName":"lorcaserin","genericName":"lorcaserin","approvalYear":"2012","relationship":"same-class"},{"drugId":"setmelanotide","brandName":"setmelanotide","genericName":"setmelanotide","approvalYear":"2020","relationship":"same-class"},{"drugId":"topiramate","brandName":"topiramate","genericName":"topiramate","approvalYear":"1996","relationship":"same-class"},{"drugId":"ephedrine","brandName":"ephedrine","genericName":"ephedrine","approvalYear":"","relationship":"same-class"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-class"},{"drugId":"naltrexone","brandName":"naltrexone","genericName":"naltrexone","approvalYear":"1984","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05209984","phase":"PHASE3","title":"A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-04","conditions":["Overweight","Obesity"],"enrollment":0,"completionDate":"2028-03"},{"nctId":"NCT05209997","phase":"","title":"Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2024-12-01","conditions":["Overweight","Obesity"],"enrollment":0,"completionDate":"2025-12-01"},{"nctId":"NCT05821543","phase":"PHASE4","title":"Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-07-03","conditions":["Obesity"],"enrollment":240,"completionDate":"2021-05-21"},{"nctId":"NCT00537810","phase":"PHASE4","title":"Treatment of Binge Eating in Obese Patients in Primary Care","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-09","conditions":["Obesity","Binge Eating"],"enrollment":104,"completionDate":"2012-10"},{"nctId":"NCT00829283","phase":"NA","title":"Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-11","conditions":["Obesity","Binge Eating"],"enrollment":191,"completionDate":"2013-11"},{"nctId":"NCT01170364","phase":"PHASE4","title":"Studying the Effects of Sibutramine on Eating Behavior","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2009-02","conditions":["Obesity"],"enrollment":14,"completionDate":"2010-10"},{"nctId":"NCT01597609","phase":"PHASE1","title":"A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-22","conditions":["Obesity"],"enrollment":60,"completionDate":"2010-03-04"},{"nctId":"NCT00533481","phase":"PHASE2","title":"Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-02","conditions":["Obesity"],"enrollment":497,"completionDate":"2004-12"},{"nctId":"NCT00115063","phase":"PHASE4","title":"LOSS- Louisiana Obese Subjects Study","status":"TERMINATED","sponsor":"Pennington Biomedical Research Center","startDate":"2005-07","conditions":["Obesity"],"enrollment":390,"completionDate":"2008-01"},{"nctId":"NCT00914212","phase":"PHASE1","title":"A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-05","conditions":["Obesity"],"enrollment":15,"completionDate":"2009-08"},{"nctId":"NCT00212173","phase":"NA","title":"Adolescent Weight Management Study","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"","conditions":["Protocol #1:Behavioral Therapy + Placebo or Sibutramine","Protocol #2: Behavioral Therapy + Meal Replacement or Conventional Food"],"enrollment":120,"completionDate":"2007-08"},{"nctId":"NCT00402077","phase":"PHASE2","title":"A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-11","conditions":["Overweight","Obesity"],"enrollment":258,"completionDate":"2007-08"},{"nctId":"NCT00037752","phase":"NA","title":"Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2002-09","conditions":["Cardiovascular Diseases","Heart Diseases","Obesity"],"enrollment":436,"completionDate":"2008-08"},{"nctId":"NCT00729963","phase":"PHASE4","title":"Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients","status":"COMPLETED","sponsor":"Laval University","startDate":"2004-01","conditions":["Obstructive Sleep Apnea","Obesity","Hypertension"],"enrollment":45,"completionDate":"2007-09"},{"nctId":"NCT01421706","phase":"PHASE1","title":"Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects","status":"COMPLETED","sponsor":"Inje University","startDate":"2008-07","conditions":["Healthy"],"enrollment":20,"completionDate":"2009-07"},{"nctId":"NCT01475019","phase":"PHASE4","title":"The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2004-01","conditions":["Obesity","Polycystic Ovaries Syndrome"],"enrollment":200,"completionDate":"2012-12"},{"nctId":"NCT00993421","phase":"PHASE2","title":"A Weight Loss Study in Overweight Men and Women","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2009-10","conditions":["Obesity"],"enrollment":343,"completionDate":"2010-06"},{"nctId":"NCT00433641","phase":"PHASE4","title":"Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-07","conditions":["Obesity"],"enrollment":181,"completionDate":"2007-11"},{"nctId":"NCT01047657","phase":"PHASE3","title":"Effects of Weight Loss in Obese Difficult-to-treat Asthmatics","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2009-11","conditions":["Asthma","Obesity","Weight Loss"],"enrollment":33,"completionDate":"2010-12"},{"nctId":"NCT01184560","phase":"NA","title":"Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2010-02","conditions":["Obesity"],"enrollment":174,"completionDate":"2010-07"},{"nctId":"NCT00234832","phase":"PHASE3","title":"A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-01","conditions":["Obesity"],"enrollment":10777,"completionDate":"2009-11"},{"nctId":"NCT00165685","phase":"PHASE3","title":"A Comparative Study of KES524 in Patients With Obesity Disease","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2004-07","conditions":["Obesity"],"enrollment":0,"completionDate":"2007-03"},{"nctId":"NCT00330525","phase":"PHASE2","title":"Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-01","conditions":["Obesity","Overweight"],"enrollment":72,"completionDate":"2006-03"},{"nctId":"NCT01023139","phase":"NA","title":"\"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention\"","status":"UNKNOWN","sponsor":"Brooke Army Medical Center","startDate":"2009-04","conditions":["Obesity"],"enrollment":100,"completionDate":"2011-03"},{"nctId":"NCT00134199","phase":"PHASE2,PHASE3","title":"A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-03","conditions":["Obesity"],"enrollment":282,"completionDate":"2005-11"},{"nctId":"NCT00941382","phase":"PHASE3","title":"Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients","status":"UNKNOWN","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2008-11","conditions":["Obesity"],"enrollment":60,"completionDate":"2009-09"},{"nctId":"NCT00537420","phase":"PHASE2","title":"A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects","status":"COMPLETED","sponsor":"Nastech Pharmaceutical Company, Inc.","startDate":"2007-10","conditions":["Obesity"],"enrollment":551,"completionDate":"2008-09"},{"nctId":"NCT00234988","phase":"PHASE4","title":"A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-06","conditions":["Obesity"],"enrollment":93,"completionDate":""},{"nctId":"NCT00679653","phase":"PHASE3","title":"Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-02","conditions":["Obesity","Hypertension"],"enrollment":171,"completionDate":""},{"nctId":"NCT00677391","phase":"PHASE3","title":"Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-12","conditions":["Obesity"],"enrollment":103,"completionDate":""},{"nctId":"NCT00645255","phase":"PHASE3","title":"Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects","status":"TERMINATED","sponsor":"Abbott","startDate":"1998-09","conditions":["Obesity","Weight Loss"],"enrollment":466,"completionDate":""},{"nctId":"NCT00402584","phase":"PHASE3","title":"A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-08","conditions":["Binge Eating Disorder","Obesity"],"enrollment":304,"completionDate":""},{"nctId":"NCT00261911","phase":"PHASE3","title":"A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-07","conditions":["Obesity"],"enrollment":498,"completionDate":"2002-02"},{"nctId":"NCT00463112","phase":"PHASE4","title":"Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2004-03","conditions":["Obesity","Polycystic Ovary Syndrome"],"enrollment":80,"completionDate":"2006-09"},{"nctId":"NCT00044187","phase":"PHASE4","title":"The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2001-04","conditions":["Schizophrenia","Psychotic Disorders","Bipolar Disorder"],"enrollment":130,"completionDate":"2003-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000022111","MMSL":"d04260","NDDF":"007298","UNII":"WV5EC51866","VUID":"4024106","CHEBI":"CHEBI:9137","VANDF":"4021089","INN_ID":"6124","RXNORM":"1294535","UMLSCUI":"C0074493","chemblId":"CHEMBL3989830","ChEMBL_ID":"CHEMBL1419","KEGG_DRUG":"D02571","DRUGBANK_ID":"DB01105","PUBCHEM_CID":"5210","SNOMEDCT_US":"108373009","IUPHAR_LIGAND_ID":"2586","SECONDARY_CAS_RN":"125494-59-9","MESH_SUPPLEMENTAL_RECORD_UI":"C058254"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1269,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A08AA10","allCodes":["A08AA10"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1997","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-11-22T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:36:33.531633+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}